Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07464314 · ClinicalTrials.gov registry record · Phase 1
A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
A Phase 1 study, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 225
- Enrollment target
NCT07464314: Recruiting Phase 1 study, sponsored by GlaxoSmithKline.
NCT07464314 is a Phase 1 study that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 225 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (275% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07464314, a Phase 1 study, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 225 participants
- Enrollment target
Study Summary
This early-stage study will look at a new mRNA vaccine that combines defenses against both seasonal flu and COVID-19 in terms of its safety and how it builds protection. Healthy adults aged 65 to 85 will receive different doses of this new vaccine, a standard flu vaccine, or COVID-19 vaccine. The study will assess any side effects or health issues, and additional blood samples will be collected at specific times to evaluate how well participants bodies build protection against the flu and COVID-19.
Primary Outcome
The assessed toxicity grades for laboratory value abnormalities will be defined as follows: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, and Grade 4 = Potentially life-threatening.
Interventions
- BIOLOGICAL Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine
- BIOLOGICAL Licensed Seasonal Influenza Vaccine
- BIOLOGICAL Licensed COVID-19 Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2026-03-09 |
| Est. Completion | 2027-06-03 |
| Phase | Phase 1 |
What NCT07464314 shows while recruiting
NCT07464314 is an interventional study that assigns participants to a tested intervention. The registered 225 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (275% higher).
The record links to 0 conditions, and to 3 interventions - of which Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine is the first listed.
NCT07464314 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07464314 about?
NCT07464314 is a clinical study titled "A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults". This early-stage study will look at a new mRNA vaccine that combines defenses against both seasonal flu and COVID-19 in terms of its safety and how it builds protection. Healthy adults aged 65 to 85 will receive different doses of this new vaccine, a standard flu vaccine, or COVID-19 vaccine. The st...
What is the current status of trial NCT07464314?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 225 participants. The study started on 2026-03-09. Estimated completion is 2027-06-03.
What interventions are being tested in trial NCT07464314?
The interventions under investigation include: Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine (BIOLOGICAL), Licensed Seasonal Influenza Vaccine (BIOLOGICAL), Licensed COVID-19 Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT07464314?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07464314's enrollment target sits among peer trials
225 223rd of 2000 higher than 1,774 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03955445 · 225 participants · Phase 3
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
- NCT04054310 · 225 participants · NA
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- NCT04480554 · 225 participants · Phase 2
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
- NCT04888104 · 225 participants
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI